Retrospective Case Study to Determine the Correlation of Patient Outcome to the ChemoFx Assay in Cases With Late Stage Endometrial Cancer
This is a multicenter, retrospective chart review study of de-identified drug response
marker results and a limited data set of clinical outcome data. Data from approximately 70
cases will be collected from approximately 10 study sites and correlated to the ChemoFx drug
response marker results. The outcome of progression free survival will be defined as the
period of time between the first dose of chemotherapy following the report of the marker
result until clinical progression or death. Objective response will be measured from the
first dose of chemotherapy following the report of the marker result until progression or
change in therapy. Overall Survival will be measured from the start of chemotherapy to the
actual date of death.
Observational
Observational Model: Case-Only, Time Perspective: Retrospective
Holly Gallion, MD
Study Chair
Vice President, Clinical Affairs
United States: Institutional Review Board
PT-106
NCT01049126
July 2009
February 2010
Name | Location |
---|---|
Precision Therapeutics, Inc. | Pittsburgh, Pennsylvania 15203 |